European Investment Bank lends €30m to Dutch biotech firm VectorY
The European Investment Bank is lending €30 million to Dutch biotech firm VectorY Therapeutics as it develops potential treatments for ALS and other neurodegenerative diseases.
Review information is loading.
The European Investment Bank is lending €30 million to Amsterdam-based VectorY Therapeutics to support its work on treatments for neurodegenerative diseases, including ALS, Huntington’s disease and Alzheimer’s disease.
VectorY is developing a method to deliver genetic instructions into cells in the central nervous system. The company says those instructions can prompt cells to produce engineered antibodies intended to counter disease processes. Its technology is designed to remain active for a long time after a single administration.
VectorY chief executive Jim Scibetta said the EIB’s support would help accelerate development of the company’s platform and advance potential treatments for neurodegenerative diseases.
Sign in to give this article a thumbs up or down.
About this discussion and AI questions
Private test discussion. Comments are readers’ views and are not yet automatically fact-checked. Editing is available for 60 seconds after posting.
Sign in with a confirmed reader account and choose a username to read comments and participate.
Sorting applies to top-level comments; replies remain oldest first. New comments and likes can change the order. Refresh for the current ranking.
Loading comments…